Andexanet-Alfa-Associated Heparin Resistance in the Context of Hemorrhagic Stroke.
Neurocrit Care
; 37(2): 372-376, 2022 10.
Article
em En
| MEDLINE
| ID: mdl-35931915
ABSTRACT
BACKGROUND:
With a growing number of patients on new oral anticoagulants, interest in reversal agents is rising. Andexanet alfa is used for reversal of factor Xa inhibitors in intracranial hemorrhage.METHODS:
We provide a brief review on andexanet-alfa-associated heparin resistance and discuss potentially critical situations from different clinical perspectives.RESULTS:
Case reports point out that andexanet alfa can cause unresponsiveness to heparin, leading to catastrophic events. As a result, regulatory bodies have issued warning notices to avoid heparinization parallel to the use of andexanet alfa.CONCLUSIONS:
Although well known to hematologists, the phenomenon is underrecognized among stroke clinicians. However, patients with intracranial hemorrhage frequently undergo endovascular or surgical interventions that require periprocedural administration of heparin.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Heparina
/
Acidente Vascular Cerebral Hemorrágico
Tipo de estudo:
Risk_factors_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article